AKT1 and non-small cell lung carcinoma: In contrast, in EGFR-mutated NSCLC, PD-L1 can be constructively upregulated by EGFR activation and its downstream signaling pathways, such as JAK/STAT/Ras/RAF/MEK/ERK/PI3K/AKT/mTOR (37).